Kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Kirsty will be available as a single-patient-use prefilled …

Jul 15, 2025 · The FDA has approved Kirsty, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions.

Learn about Kirsty, dosing, proper use and what to know before beginning treatment

Aug 19, 2025 · Kirsty for injection: 100 units/mL (U-100) is a clear and colorless solution available as a 10 mL multiple-dose vial and a 3 mL single-patient-use prefilled pen. The safety and …

Insulin aspart is a rapid-acting insulin. It takes 10 to 20 minutes to begin working after the injection, has its maximum effect between 1 hour and 3 hours, and stops working after 3 to 5 …

Use KIRSTY in accordance with the insulin pump system’s instructions for use. Train patients using continuous subcutaneous insulin fusion pump therapy to administer insulin by injection …

Refer to the insulin infusion pump user manual to see if KIRSTY or NOVOLOG can be used with the insulin pump, in which case KIRSTY can be used with the pump. Use in accordance with …

Aug 7, 2025 · Kirsty has already received regulatory approval for sale in more than 40 countries, including Canada, Japan, Australia, and across most of Europe. Health Canada granted its …

Kirsty MacColl’s death remains one of the most heartbreaking losses in modern music. Not only because she was taken at the height of her creativity, but because her final moments were …

Jul 16, 2025 · The US Food and Drug Administration has approved the first rapid-acting interchangeable biosimilar product, Kirsty (insulin aspart-xjhz), as a 3 mL single-patient-use …